Wuhan General Group
UnverifiedM2Bio Sciences, a company that develops innovative healthcare solutions through cannabis and mushroom-based sciences, with focus on psilocybin and cannabinoids, targeting drug discovery and treatment sales in anxiety, depression, ADHD.
Launch date
Employees
Market cap
$5.5k
Net debt
-
Enterprise valuation
$6k (Public information from Jun 2024)
Share price
$0.0001 WUHN
Reno Nevada (HQ)
Deals in current and previous year:
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | $0.0 | round | |
$450k | Post IPO Equity | ||
| Total Funding | 000k | ||
